Longboard Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for attending Citi's 16th Annual BioPharma Conference. I'm Neena Bitritto-Garg. I'm one of the biotech analysts here at Citi if you don't know me, and I'm pleased to be joined for our next fireside chat by Longboard Pharmaceuticals' management team, including CEO -- President and CEO, Kevin Lind; and Chief Medical Officer, Phil Perera. And today we're going to talk about the Company's CNS pipeline, including LP352, the Phase 1 data update that the Company released earlier this morning.
(Conference Instructions). And so just to start off, I'm actually going to pass it over to Kevin to make some opening remarks before getting into questions. Kevin?
Thanks, Neena. Appreciate it. Just a reminder, we're going to be making forward-looking statements. Please refer to our SEC filings.
We are excited to be moving Longboard forward. We have three assets with best-in-class
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
